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Multivariate Analysis of Clinical Predictors of Overall Survival (n¼92)
Characteristic HR (95% CI) P-Value
KPS <90 2.08 (1.10-3.92) 0.023
HCT-CI 4+ 2.77 (1.44-5.32) 0.002
Not in CR 1.16 (0.59-2.32) 0.664
Age >65 1.32 (0.70-2.51) 0.393
Plt Engraftment >15 Days 2.48 (1.21-5.08) 0.013
ANC Engraftnent >14 Days 1.58 (0.84-3.00) 0.156
+ aGVHD 4.31 (1.80-10.33) 0.001
+ cGVHD 1.24 (0.53-2.95) 0.618
Risk Score: High/Very High 1.40 (0.67-2.90) 0.371
*All variables were normalized to HR¼1
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Celiac Disease Transmitted By Unrelated Cord Blood Stem
Cell Transplantation (CBST)
Abdullah Baothman. King Saud University for Heatlth Science,
Jeddah, Saudi Arabia, Oncology, King Abdulaziz Medical Center,
Jeddah, Saudi Arabia
Background: Celiac disease is due to intolerance to certain
cereal proteins leading to immune-mediated small bowel
villous atrophy and malabsorption. Speciﬁcally, the gliadin
component of wheat, and the prolamin component of rye
and barley are implicated in causing disease. BMT and CBST
have been known to transmit immune associated diseases
such as diabetes mellitus immune thrombocytopenic pur-
pura from an affected donor to transplant recipient.
Methods & Results: We observed the occurrence of Celiac
disease in a patient a year following cord blood stem cell
transplantation (CBST) for acute myelogenous leukemia
(AML- FAB M2) in complete second remission (CR-2). The
patient had no history of celiac disease prior to CBST nor any
family member. The cord donor was HLA-identical unrelated
male donor with HLA types: A3, B7 (w6), DR (B1), DR (B5).
The family history of the donor was unavailable for celiac
disease. The CBST was complicated by grade 2 skin Graft
versus Host Disease (GVHD), which responded to steroid
therapy. A year post transplantation she developed persis-
tent mucous diarrhea with tinge of blood associated with
abdominal cramps. Investigations for infectious causes such
as CMV enteritis were negative and colonsocopy did not
reveal any evidence of GVHD. Gastrointestinal symptoms
persisted and did not respond to steroid and prograf therapy.
Subsequent duodenal and jejunal biopsy revealed subtotal
villous atrophy with cryptic hyperplasia suggestive of celiac
disease. Antigliadin IgA and IgG, reticulin IgA and Endomy-
sial IgA andibodies were elevated. A diagnosis of post-CBST
coeliac disease was made. She responded well to gluten-free
diet and became symptom-free.
Discussion & Conclusion: A literature review identiﬁes only
from donor to recipient one previous example of trans-
mission of celiac disease following HSCT. This case could be
the second case of celiac disease following transplantation
and the ﬁrst one post CBST. An association of celiac disease
with some HLA types, including DQA1.0501, and DQB1.0201,
in conjunction with the haplotypes A30, B18, DR3, DRw52,
and DQ2 was recently noted. The donor of this case exhibit
HLA DQ A1.0501 and DQ B1.0201 alleles. The ﬁndings sug-
gest transfer of celiac disease by cord stem cells and conﬁrm
the immune nature of the disease. In addition the pro-
pensity to develop T-cell non-Hodgkin lymphoma and
transmission of celiac disease by CBST support T cell concept
in celiac disease. Autoimmune enteropathy should be
considered in patient with persistent diarrhea post hemo-
poietic stem cell transplant.
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Results of a Phase II Trial
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Introduction: Non-myeloablative (NMA) allogeneic trans-
plant for the treatment of hematologic malignancies has
become the standard of care for patients unable to tolerate
myeloablative conditioning. The BuFluTBI transplant regimen
was designed with the primary goal of reducing non-relapse
mortality (NRM) while maximizing primary disease control
in older and inﬁrm patients.
Methods: Patients with high-risk hematologic malignancies
were given an outpatient conditioning regimen of busulfan
3.2 mg/kg IV on day -5, ﬂudarabine 30 mg/m2 IV on days -4,
-3, -2, and 200 cGy of total body irradiation (TBI). Sources of
hematopoietic stem cells were either from related or unre-
lated donors (at least 7/8 antigen match). GVHD prophylaxis
was given with cyclosporine and mycophenolate mofetil.
Clinical predictors of response were evaluated utilizing Cox
Proportional Hazards Model.
Results: 147 patients were enrolled from 2005-2011; 86
(59%) with myeloid disease and 61 (41%) with lymphoid
disease. Themedian agewas 64, and themedian comorbidity
index (HCT-CI) score was 3. The overall survival (OS), with 2
yearsmedian follow-up, was 60% at 1 year and 48% at 2 years,
with projected OS 37% at 5 years. Relapse rates were 29% at 1
year and 33% at 2 years, with relapse mortality of 13% at 1
year, and 20% at 2 years. NRM at 1 year was 27% and 33% at 2
years. 54% of patients developed early or late grade II-IV
acute GVHD (aGVHD), and 67% of patients developed cGVHD
within 2 years. On multivariate analysis, amongst 92 evalu-
able patients, HCT-CI score greater than 4, pre-transplant KPS
<90, delayed platelet engraftment >15 days, and aGVHD
were found to be independent predictors of poor survival as
demonstrated in the table.
Conclusions: In an inﬁrm elderly population with a high
HCT-CI, BuFluTBI is an effective regimen with favorable OS
with acceptable levels of NRM.330
What Happens Next? - Outcomes after Relapse Following
Allogeneic Haematopoietic Stem Cell Transplant for Acute
Leukemia in Adults
Louisa Brown 1, Philip Rowlings 2. 1 Haematology, Calvary
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Background: Relapse after allogeneic stem cell transplant
(allo-HSCT) for acute leukaemia (AL) remains a major
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S216challenge. Despite advances in allo-HSCT reducing risk of
morbidity andmortality, relapse has not altered signiﬁcantly.
We performed a single institution review of relapse
following allo-HSCT in patients with AL examining salvage
therapy and characteristics of long term survivors.
Methods: All adult patients who proceeded to an allo-HSCT
for AL from 1998-2012 (n¼100) were reviewed. 24 relapsed
following allo-HSCT and a detailed review of salvage treat-
ments and outcomes was made. Probability of overall sur-
vival (POS) and 95% conﬁdence interval (CI) were calculated
by actuarial method.
Results: The 5 year POS of the 100 patients with AL pro-
ceeding to allo-HSCT was 71 % (CI 61-80%). Of 24 relapsing
after allo-HSCT, 17 had initial diagnosis AML, and 7 ALL. The
AML groupmedian agewas 49y (range 22-65), 53%male. Ten
patients received sibling donors, 6 unrelated donors and 1
patient a related haplo-identical donor. Relapses were
mostly systemic (14) and extra medullary (EM) 3 of the 17
cases. Median time to relapse was 13 months (3-57). Salvage
treatments were: second allo-HSCT +/- chemotherapy
(chemo) (n¼5); donor lymphocyte infusion (DLI) +/- chemo
(n¼5); chemo +/- withdrawal of immunosuppression (WI)
(n¼4); or palliative/supportive care (n¼3). Ten patients (57%)
achieved complete response (CR), and CR was maintained by
8 patients (47%), with a median follow up 34 months (range
8-66). All deaths (n¼9) were due to disease. All 3 patients
with EM relapse are in ongoing remission.
In the ALL group (n¼7) median age was 22y (range 19-
52), 57% of male. 3 were sibling donor transplants, 3 unre-
lated and 1 patient received a double cord. Relapse was
systemic in 5 patients, and EM in 2. Median time to relapse
was 13 months (range 3-57). Salvage treatments comprised:
chemo +/- WI (n¼3), second allo-HSCT +/- salvage chemo
(n¼2), DLI +/- salvage chemo (n¼1), with 1 patient receiving
novel monoclonal antibody therapy. Three patients achieved
a CR, however, all died, 2 of disease progression. Two patients
remain alive in PR with ongoing salvage treatment to be
determined.
Conclusions: Despite advances in allo-HSCT, long term sur-
vival outcomes for patients with ALL who relapse after allo-
HSCT remain poor. However, in contrast, for patients with
AML who relapse, durable long-term remissions can be
achieved with salvage therapy (with and without second
allo-HSCT) with almost half of our patients (47%) in ongoing
CR at a median of 34 months (range 8-66). As shown in other
studies EM relapse, may be salvaged with good long term
results.331
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Background: Over the last decade, unrelated donors have
become a vital resource for hematopoietic stem cell trans-
plantation (HSCT) and the number of allogeneic HSCT (allo-
HSCT) has increased signiﬁcantly. While invasive fungal
infections (IFIs) remain major concerns in these patients,
data regarding impact of these infections on mortality,length of hospital stay, and hospital charge are limited in the
United States at a national level. Additionally, with many
updates in transplant practice, risk factors for IFIs in these
patients may have changed.
Methods: To assess risk factors and impact of IFIs on
mortality, length of hospital stay, and hospital charges, a
quantitative and cross-sectional design was used to analyze
secondary data from the 2010 Healthcare Cost and Utiliza-
tion Project - Nationwide Inpatient Sample (HCUP NIS)
database. Chi-square test, Mann-Whitney test, and multiple
logistic regression were used for statistical analyses.
Results: A total of 5,753 weighted hospital records of allo-
HSCT were identiﬁed with a mean age of 44.8  19.1 years.
The IFI rate was 7.8% (451), with aspergillosis (30.6%) and
candidiasis (9.6%) as the two most common IFIs. Compared
to patients without IFIs, patients with IFIs had nearly 5 times
higher mortality (25.1% vs. 5.1%), longer hospital stays, and
higher hospital charges (p < .01). Multiple regression ana-
lyses on risk factors conﬁrmed presence of graft-versus-host
disease as a recognized risk factor for IFIs. However, younger
age, female gender, and related donors were also identiﬁed
as risk factors for IFIs in this analysis. The underlying reasons
for these unexpected ﬁndings will be explored.
Conclusions: An analysis of a large U.S. inpatient database
conﬁrmed that allo-HSCT patients with IFIs have higher
mortality and higher health care costs. The risk factors for
IFIs have been identiﬁed that could enable better manage-
ment and control of these infections.332
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Background: ABO typing is not readily available within
donor databases. ABO incompatibility between donor and
recipient is not considered a hurdle to an allogeneic he-
matopoietic stem cell transplantation (ALLOSCT). Conﬂicting
data still exist as to its inﬂuence on graft-versus-host disease
(GVHD), relapse, and survival.
Method: We retrospectively examined the impact of ABO
compatibility on outcomes of 109 patients who underwent
matched unrelated donor (MUD), matched related (REL) and
cord blood (CBU) ALLOSCT at our institution since 01/01/
2010.
Results: Median age was 58 years (range, 19.9- 83.6); 33
(30%) were female; 64 (59%) patients had a myeloid, 34 (31%)
lymhoid, 8 (7%) plasma cell and 3 (3%) had other disorder; 57
(52%) patients received myeloablative, 25 (23%) non-
myeloablative and 27 (25%) received reduced intensity con-
ditioning. The stem cell sources were represented by 78
(72%) MUDs,15 (14%) RELs and 16 (15%) CBUs. 80 (86%) of the
MUD and REL transplants were 10/10, 11 (13%) were 9/10, 1
